Performance of McDonald 2017 multiple sclerosis diagnostic criteria and evaluation of genetic ancestry in patients with a first demyelinating event in Argentina
Restricted accessResearch articleFirst published online April, 2023
Performance of McDonald 2017 multiple sclerosis diagnostic criteria and evaluation of genetic ancestry in patients with a first demyelinating event in Argentina
Information on performance of multiple sclerosis (MS) diagnostic criteria is scarce for populations from Latin America, Asia, or the Caribbean.
Objective:
To assess performance of revised 2017 McDonald criteria as well as evaluate genetic ancestry in a group of MS patients from Argentina experiencing a debut demyelinating event.
Methods:
Demographic and clinical characteristics, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) findings and new T2 lesions were recorded at baseline and during relapses. Diagnostic accuracy in predicting conversion to clinically defined MS (CDMS) based on initial imaging applying revised 2017 criteria was evaluated and genetic ancestry-informative markers analyzed.
Results:
Of 201 patients experiencing their first demyelinating event (median follow-up 60 months), CDMS was confirmed in 67. We found 2017 diagnostic criteria were more sensitive (84% vs 67%) and less specific (14% vs 33%) than 2010 criteria, especially in a group of patients revised separately, presenting positive oligoclonal bands (88% vs 8%). Genetic testing performed in 128 cases showed 72% of patients were of European ancestry and 27% presented genetic admixture.
Conclusion:
2017 McDonald criteria showed higher sensitivity and lower specificity compared with 2010 criteria, shortening both time-to-diagnosis and time-to-treatment implementation.
SchumacherGABeebeGKiblerRF, et al. Problems of experimental trials of therapy in Multiple Sclerosis: Report by the panel on the evaluation of experimental trials of therapy in Multiple Sclerosis. Ann N Y Acad Sci1965; 122: 552–568.
2.
PoserCMPatyDWScheinbergL, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol1983; 13(3): 227–231.
3.
McDonaldWICompstonAEdanG, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol2001; 50(1): 121–127.
4.
PolmanCHReingoldSCEdanG, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.”Ann Neurol2005; 58(6): 840–846.
5.
PolmanCHReingoldSCBanwellB, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69(2): 292–302.
6.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17(2): 162–173.
7.
Pagani CassaráFCurbeloMCVazquezG, et al. Application of the 2017 McDonald criteria for the diagnosis of multiple sclerosis after a first demyelinating event in patients from Argentina. Mult Scler Relat Disord2020; 41: 102043.
8.
BurchardEGZivECoyleN, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med2003; 348(12): 1170–1175.
9.
CorachDLaoOBobilloC, et al. Inferring continental ancestry of Argentineans from Autosomal, Y-chromosomal and mitochondrial DNA. Ann Hum Genet2010; 74(1): 65–76.
10.
KosoyRNassirRTianC, et al. Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat2009; 30(1): 69–78.
11.
GiovannoniGTomicDBrightJR, et al. “No evident disease activity”: The use of combined assessment in the management of patients with multiple sclerosis. Mult Scler2017; 23(9): 1179–1187.
12.
FreedmanMSThompsonEJDeisenhammerF, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: A consensus statement. Arch Neurol2005; 62(6): 865–870.
13.
PodiniDVallonePM. SNP genotyping using multiplex single base primer extension assays. Methods Mol Biol2009; 578: 379–391.
14.
RosenbergNA. Standardized subsets of the HGDP-CEPH Human Genome Diversity Cell Line Panel, accounting for atypical and duplicated samples and pairs of close relatives. Ann Hum Genet2006; 70(Pt 6): 841–847.
15.
PatruccoL. Application of the McDonald criteria in Latin America. Mult Scler J Exp Transl Clin2017; 3(3): 2055217317721943.
16.
RojasJIRomanoMPatruccoL, et al. A systematic review about the epidemiology of primary progressive multiple sclerosis in Latin America and the Caribbean. Mult Scler Relat Disord2018; 22: 1–7.
17.
PatruccoLRojasJIMiguezJS, et al. Application of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinean cohort of patients with clinically isolated syndromes. Mult Scler2013; 19(10): 1297–1301.
18.
PryceGBakerD. Oligoclonal bands in multiple sclerosis; Functional significance and therapeutic implications. Mult Scler Relat Disord2018; 25: 131–137.
19.
ArrambideGTintoreMEspejoC, et al. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain2018; 141(4): 1075–1084.
20.
GamaPDMachado LdosRLivramentoJA, et al. Study of oligoclonal bands restricted to the cerebrospinal fluid in multiple sclerosis patients in the city of São Paulo. Arq Neuropsiquiatr2009; 67(4): 1017–1022.
21.
NegrottoLMarrodanMFiolMP, et al. Absence of latitudinal gradient in oligoclonal bands prevalence in Argentina. Mult Scler Relat Disord2020; 46: 102582.
22.
van der Vuurst de VriesRMMescheriakovaJYWongYYM, et al. Application of the 2017 revised McDonald criteria for multiple sclerosis to patients with a typical clinically isolated syndrome. JAMA Neurol2018; 75(11): 1392–1398.
23.
HyunJWKimWHuhSY, et al. Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome. Mult Scler2019; 25(11): 1488–1495.
24.
GobbinFZanoniMMarangiA, et al. 2017 McDonald criteria for multiple sclerosis: Earlier diagnosis with reduced specificity?Mult Scler Relat Disord2019; 29: 23–25.
25.
FilippiMPreziosaPMeaniA, et al. Performance of the 2017 and 2010 revised McDonald criteria in predicting MS diagnosis after a clinically isolated syndrome: A MAGNIMS study. Neurology2022; 98(1): e1–e14.
26.
SouissiAMrabetSNasriA, et al. Multiple sclerosis 2017 McDonald criteria are also relevant for Tunisians. Mult Scler Relat Disord2020; 43: 102161.
27.
HabekMPavičićTRuškaB, et al. Establishing the diagnosis of multiple sclerosis in Croatian patients with clinically isolated syndrome: 2010 versus 2017 McDonald criteria. Mult Scler Relat Disord2018; 25: 99–103.
28.
MarrodanMPiedrabuenaMAGaitanMI, et al. Performance of McDonald 2017 multiple sclerosis diagnostic criteria and evaluation of genetic ancestry in patients with a first demyelinating event in Argentina. Mult Scler2023 (in press).
29.
TintoreMCobo-CalvoACarbonellP, et al. Effect of changes in MS diagnostic criteria over 25 years on time to treatment and prognosis in patients with clinically isolated syndrome. Neurology2021; 97(17): e1641–e1652.
30.
ArrambideGTintoreM. Diagnosis of multiple sclerosis: What is changing?Expert Rev Neurother2020; 20(8): 743–746.
31.
SormaniMPTintorèMRovarisM, et al. Will Rogers phenomenon in multiple sclerosis. Ann Neurol2008; 64(4): 428–433.
32.
TintoreMArrambideGOtero-RomeroS, et al. The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. Mult Scler2020; 26(13): 1658–1669.
33.
ZiemssenTDerfussTde StefanoN, et al. Optimizing treatment success in multiple sclerosis. J Neurol2016; 263(6): 1053–1065.
34.
ParolinMLToscaniniUFVelázquezIF, et al. Genetic admixture patterns in Argentinian Patagonia. PLoS ONE2019; 14(6): e0214830.
35.
AvenaSViaMZivE, et al. Heterogeneity in genetic admixture across different regions of Argentina. PLoS ONE2012; 7(4): e34695.
36.
SinhaMLarkinEKElstonRC, et al. Self-reported race and genetic admixture. N Engl J Med2006; 354(4): 421–422.
37.
CollinsFS. What we do and don’t know about “race,” “ethnicity,” genetics and health at the dawn of the genome era. Nat Genet2004; 36(11 Suppl.): S13–S15.
